Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,160 | 822 | 47.4% |
| Consulting Fee | $10,950 | 8 | 36.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,150 | 1 | 10.5% |
| Education | $1,620 | 23 | 5.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| INSYS Therapeutics Inc | $7,930 | 12 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $3,396 | 72 | $0 (2024) |
| Global Blood Therapeutics, Inc. | $3,022 | 7 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $1,624 | 80 | $0 (2024) |
| PUMA BIOTECHNOLOGY, INC. | $1,160 | 6 | $0 (2024) |
| Amgen Inc. | $1,083 | 45 | $0 (2023) |
| Merck Sharp & Dohme LLC | $978.06 | 70 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $927.88 | 61 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $876.60 | 53 | $0 (2024) |
| Sirtex Medical Inc | $782.83 | 33 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,405 | 123 | AstraZeneca Pharmaceuticals LP ($366.84) |
| 2023 | $2,369 | 133 | Celgene Corporation ($226.39) |
| 2022 | $4,323 | 147 | E.R. Squibb & Sons, L.L.C. ($1,887) |
| 2021 | $5,997 | 110 | Global Blood Therapeutics, Inc. ($2,979) |
| 2020 | $1,343 | 82 | Amgen Inc. ($268.71) |
| 2019 | $2,712 | 95 | Puma Biotechnology, Inc. ($1,101) |
| 2018 | $7,911 | 99 | INSYS Therapeutics Inc ($6,581) |
| 2017 | $2,819 | 65 | INSYS Therapeutics Inc ($1,348) |
All Payment Transactions
854 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Oncology | ||||||
| 12/17/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $15.30 | General |
| 12/10/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Oncology | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.53 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $28.92 | General |
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.98 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/24/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: HORMONE THERAPY | ||||||
| 10/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.40 | General |
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.17 | General |
| 10/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $21.64 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $30.35 | General |
| Category: NONE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 453 | 999 | $217,985 | $92,647 |
| 2022 | 7 | 339 | 836 | $187,940 | $76,020 |
| 2021 | 9 | 406 | 1,051 | $236,315 | $97,401 |
| 2020 | 7 | 332 | 1,059 | $254,730 | $88,823 |
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 132 | 347 | $83,280 | $36,629 | 44.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 94 | 374 | $59,840 | $25,662 | 42.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 48 | 54 | $24,030 | $8,159 | 34.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 37 | $12,025 | $5,440 | 45.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 49 | 65 | $10,725 | $5,102 | 47.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 29 | 48 | $11,040 | $4,976 | 45.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $10,585 | $3,737 | 35.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 29 | 31 | $3,100 | $1,536 | 49.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $3,360 | $1,406 | 41.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 107 | 308 | $73,920 | $31,794 | 43.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 98 | 368 | $58,530 | $22,506 | 38.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 60 | $19,500 | $8,000 | 41.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 36 | 37 | $16,465 | $6,254 | 38.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $9,125 | $3,311 | 36.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $6,440 | $2,598 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 24 | $3,960 | $1,558 | 39.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 106 | 552 | $88,320 | $34,508 | 39.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 72 | 168 | $54,600 | $24,433 | 44.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 65 | 76 | $33,820 | $13,360 | 39.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 67 | 118 | $28,320 | $13,096 | 46.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 53 | $12,190 | $4,769 | 39.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 20 | 20 | $7,300 | $2,793 | 38.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $6,900 | $2,779 | 40.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 19 | 21 | $3,465 | $1,296 | 37.4% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2021 | 20 | 28 | $1,400 | $366.52 | 26.2% |
About Dr. Howard Benn, MD
Dr. Howard Benn, MD is a Specialist healthcare provider based in Paterson, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841364965.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Howard Benn, MD has received a total of $29,880 in payments from pharmaceutical and medical device companies, with $2,405 received in 2024. These payments were reported across 854 transactions from 71 companies. The most common payment nature is "Food and Beverage" ($14,160).
As a Medicare-enrolled provider, Benn has provided services to 1,530 Medicare beneficiaries, totaling 3,945 services with total Medicare billing of $354,890. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Practice Information
- Specialty Specialist
- Other Specialties Hematology & Oncology
- Location Paterson, NJ
- Active Since 11/20/2006
- Last Updated 01/04/2024
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1841364965
Products in Payments
- SYNDROS (Drug) $6,620
- OXBRYTA (Drug) $3,070
- SUBSYS (Drug) $1,309
- Nerlynx (Drug) $1,129
- KEYTRUDA (Biological) $887.49
- SIR-Spheres Microspheres (Device) $782.83
- OPDIVO (Biological) $691.36
- LYNPARZA (Drug) $616.62
- Lenvima (Drug) $458.28
- Stivarga (Drug) $371.01
- REBLOZYL (Biological) $333.37
- KISQALI (Drug) $297.02
- IMFINZI (Biological) $295.58
- Enhertu (Drug) $253.05
- TAGRISSO (Drug) $249.17
- Nubeqa (Drug) $245.97
- DARZALEX (Biological) $236.40
- ELIQUIS (Drug) $218.70
- NINLARO (Drug) $212.22
- PROMACTA (Drug) $210.49
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Paterson
Dr. Michael Umanoff, Md, MD
Specialist — Payments: $9,750
Lorraine Cornwell, Md, MD
Specialist — Payments: $9,151
Cathy Russo, Md, MD
Specialist — Payments: $2,547
Dr. Majhavi Kanetkar, Md, MD
Specialist — Payments: $1,139
Dr. Faizah Zuberi, M.d, M.D
Specialist — Payments: $657.71
Dr. Sheila Rao, Md, MD
Specialist — Payments: $429.18